Lilly To Pay Conn. $25M Over Zyprexa Marketing

By Erin Marie Daly

Law360, New York (September 29, 2009, 4:46 PM ET) -- Eli Lilly & Co. is set to fork over $25.1 million to settle a lawsuit brought by the Connecticut Attorney General's Office for allegedly marketing its antipsychotic Zyprexa for unapproved uses and concealing the drug's serious side effects for more than a decade.

The settlement, announced Tuesday by Connecticut Attorney General Richard Blumenthal, marks the third such deal the pharmaceutical giant has brokered with states in recent months.

Lilly reached the deal without admitting any wrongdoing, according to a consent decree filed Tuesday in the U.S....
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles